{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-26-000012","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.509043+00:00","generated_at":"2026-05-16T01:44:24.406359+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B","bullets":["Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.","Full year 2025 revenue $982.0M (+33%); net loss $416.3M ($3.32 EPS) vs $436.4M prior year.","Adj. EBITDA loss improved to $220.9M (FY) from $257.5M; free cash flow burn $233M vs $275M.","2026 guidance: revenue $1.25-1.28B (27-30% growth); Screening revenue $162-174M; volume 210k-225k tests.","Acquired MetaSight Diagnostics for $59M upfront plus up to $90M contingent consideration."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-26-000012","json":"https://secwatch.observer/filing/0001576280-26-000012.json","markdown":"https://secwatch.observer/filing/0001576280-26-000012.md","text":"https://secwatch.observer/filing/0001576280-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628026000012/0001576280-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628026000012/gh-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:44:24.406359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}